Carboxymethyl lysine induces EMT in podocytes through transcription factor ZEB2: Implications for podocyte depletion and proteinuria in diabetes mellitus

Archives of Biochemistry and Biophysics

Volumn 590, Issue , 2016, Pages 10-19

  Kumar, P Anil ^a,b   Welsh, Gavin I ^c   Raghu, G ^a   Menon, Ram K ^d   Saleem, Moin A ^c   Reddy, G Bhanuprakash ^a  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

^b UNIVERSITY OF HYDERABAD   (India)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Carboxymethyl lysine; Diabetic nephropathy; E cadherin; NF kB; Podocytes; ZEB2

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARBOXYMETHYL LYSINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; UVOMORULIN; HOMEODOMAIN PROTEIN; N(6)-CARBOXYMETHYLLYSINE; REPRESSOR PROTEIN; ZEB2 PROTEIN, RAT;

ARTICLE; CELL FRACTIONATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; PODOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; WESTERN BLOTTING; WOUND HEALING; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; KIDNEY; METABOLISM; PATHOLOGY; RAT; WISTAR RAT;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; GLYCOSYLATION END PRODUCTS, ADVANCED; HOMEODOMAIN PROTEINS; HUMANS; KIDNEY; LYSINE; NF-KAPPA B; PODOCYTES; PROTEINURIA; RATS; RATS, WISTAR; REPRESSOR PROTEINS;

EID: 84947081161     PISSN: 00039861     EISSN: 10960384     Source Type: Journal    
DOI: 10.1016/j.abb.2015.11.003     Document Type: Article

References (50)

1. P. Anil Kumar, G.I. Welsh, and M.A. Saleem Menon RK: molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus Front. Endocrinol. Lausanne 5 2014 151
2. J. Patrakka, and K. Tryggvason New insights into the role of podocytes in proteinuria Nat. Rev. Nephrol. 5 8 2009 463 468
3. C. Faul, K. Asanuma, E. Yanagida-Asanuma, K. Kim, and P. Mundel Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton Trends Cell Biol. 17 9 2007 428 437
4. P. Mundel, and S.J. Shankland Podocyte biology and response to injury J. Am. Soc. Nephrol. JASN 13 12 2002 3005 3015
5. W. Kriz, N. Gretz, and K.V. Lemley Progression of glomerular diseases: is the podocyte the culprit? Kidney Int. 54 3 1998 687 697
6. L. Barisoni, W. Kriz, P. Mundel, and V. D'Agati The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy J. Am. Soc. Nephrol. 10 1 1999 51 61
7. S.F. Bjorn, H.J. Bangstad, K.F. Hanssen, G. Nyberg, J.D. Walker, G.C. Viberti, and R. Osterby Glomerular epithelial foot processes and filtration slits in IDDM patients Diabetologia 38 10 1995 1197 1204
8. S.J. Shankland The podocyte's response to injury: role in proteinuria and glomerulosclerosis Kidney Int. 69 12 2006 2131 2147
9. G. Wolf, S. Chen, and F.N. Ziyadeh From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy Diabetes 54 6 2005 1626 1634
10. T.W. Meyer, P.H. Bennett, and R.G. Nelson Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria Diabetologia 42 11 1999 1341 1344
11. M.E. Pagtalunan, P.L. Miller, S. Jumping-Eagle, R.G. Nelson, B.D. Myers, H.G. Rennke, N.S. Coplon, L. Sun, and T.W. Meyer Podocyte loss and progressive glomerular injury in type II diabetes J. Clin. Investig. 99 2 1997 342 348
12. T. Nakamura, C. Ushiyama, S. Suzuki, M. Hara, N. Shimada, I. Ebihara, and H. Koide Urinary excretion of podocytes in patients with diabetic nephropathy Nephrol. Dial. Transpl. 15 9 2000 1379 1383
13. A.T. Petermann, R. Krofft, M. Blonski, K. Hiromura, M. Vaughn, R. Pichler, S. Griffin, T. Wada, J. Pippin, R. Durvasula, and et al. Podocytes that detach in experimental membranous nephropathy are viable Kidney Int. 64 4 2003 1222 1231
14. R.O. Estacio, and R.W. Schrier Diabetic nephropathy: pathogenesis, diagnosis, and prevention of progression Adv. Intern Med. 46 2001 359 408
15. Z. Makita, S. Radoff, E.J. Rayfield, Z. Yang, E. Skolnik, V. Delaney, E.A. Friedman, A. Cerami, and H. Vlassara Advanced glycosylation end products in patients with diabetic nephropathy N. Engl. J. Med. 325 12 1991 836 842
16. L.J. Striker, and G.E. Striker Administration of AGEs in vivo induces extracellular matrix gene expression Nephrol. Dial. Transpl. 11 Suppl. 5 1996 62 65
17. C.W. Yang, H. Vlassara, G.E. Striker, and L.J. Striker Administration of AGEs in vivo induces genes implicated in diabetic glomerulosclerosis Kidney Int. Suppl. 49 1995 S55 58
18. P. Muthenna, G. Raghu, P.A. Kumar, M.V. Surekha, and G.B. Reddy Effect of cinnamon and its procyanidin-B2 enriched fraction on diabetic nephropathy in rats Chem. Biol. Interact. 222C 2014 68 76
19. P.A. Kumar, P.Y. Reddy, P.N. Srinivas, and G.B. Reddy Delay of diabetic cataract in rats by the antiglycating potential of cumin through modulation of alpha-crystallin chaperone activity J. Nutr. Biochem. 20 7 2009 553 562
20. J.M. Forbes, M.E. Cooper, M.D. Oldfield, and M.C. Thomas Role of advanced glycation end products in diabetic nephropathy J. Am. Soc. Nephrol. JASN 14 8 Suppl. 3 2003 S254 258
21. M. Busch, S. Franke, C. Ruster, and G. Wolf Advanced glycation end-products and the kidney Eur. J. Clin. Investig. 40 8 2010 742 755
22. R. Singh, A. Barden, T. Mori, and L. Beilin Advanced glycation end-products: a review Diabetologia 44 2 2001 129 146
23. A.L. Tan, J.M. Forbes, and M.E. Cooper AGE, RAGE, and ROS in diabetic nephropathy Semin. Nephrol. 27 2 2007 130 143
24. M.D. Oldfield, L.A. Bach, J.M. Forbes, D. Nikolic-Paterson, A. McRobert, V. Thallas, R.C. Atkins, T. Osicka, G. Jerums, and M.E. Cooper Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE) J. Clin. Investig. 108 12 2001 1853 1863
25. J.H. Li, W. Wang, X.R. Huang, M. Oldfield, A.M. Schmidt, M.E. Cooper, and H.Y. Lan Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway Am. J. Pathol. 164 4 2004 1389 1397
26. L. Ni, M. Saleem, and P.W. Mathieson Podocyte culture: tricks of the trade Nephrol. Carlt. 17 6 2012 525 531
27. T.D. Schmittgen, and K.J. Livak Analyzing real-time PCR data by the comparative C(T) method Nat. Protoc. 3 6 2008 1101 1108
28. P.A. Kumar, K. Kotlyarevska, P. Dejkhmaron, G.R. Reddy, C. Lu, M.S. Bhojani, and R.K. Menon Growth hormone (GH)-dependent expression of a natural antisense transcript induces zinc finger E-box-binding homeobox 2 (ZEB2) in the glomerular podocyte: a novel action of gh with implications for the pathogenesis of diabetic nephropathy J. Biol. Chem. 285 41 2010 31148 31156
29. M. Katoh Integrative genomic analyses of ZEB2: transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1alpha, POU/OCT, and NF-kappaB Int. J. Oncol. 34 6 2009 1737 1742
30. M. Brownlee Lilly Lecture 1993. Glycation and diabetic complications Diabetes 43 6 1994 836 841
31. P.A. Kumar, M.S. Kumar, and G.B. Reddy Effect of glycation on alpha-crystallin structure and chaperone-like function Biochem. J. 408 2 2007 251 258
32. P.A. Kumar, P.S. Chitra, and G.B. Reddy Metabolic syndrome and associated chronic kidney diseases: nutritional interventions Rev. Endocr. Metab. Disord. 14 3 2013 273 286
33. M. Chen, T.M. Curtis, and A.W. Stitt Advanced glycation end products and diabetic retinopathy Curr. Med. Chem. 20 26 2013 3234 3240
34. M.C. Thomas, J.M. Forbes, R. MacIsaac, G. Jerums, and M.E. Cooper Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more? Ann. N. Y. Acad. Sci. 1043 2005 644 654
35. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 6865 2001 813 820
36. G. Wolf, and F.N. Ziyadeh Cellular and molecular mechanisms of proteinuria in diabetic nephropathy Nephron Physiol. 106 2 2007 p26 31
37. M.C. Thomas, J.M. Forbes, and M.E. Cooper Advanced glycation end products and diabetic nephropathy Am. J. Ther. 12 6 2005 562 572
38. M. Saraswat, P.Y. Reddy, P. Muthenna, and G.B. Reddy Prevention of non-enzymic glycation of proteins by dietary agents: prospects for alleviating diabetic complications Br. J. Nutr. 101 11 2009 1714 1721
39. T. Soulis, M.E. Cooper, D. Vranes, R. Bucala, and G. Jerums Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment Kidney Int. 50 2 1996 627 634
40. P. Muthenna, G. Raghu, C. Akileshwari, S.N. Sinha, P. Suryanarayana, and G.B. Reddy Inhibition of protein glycation by procyanidin-B2 enriched fraction of cinnamon: delay of diabetic cataract in rats IUBMB Life 65 11 2013 941 950
41. T. Takeda, W.Y. Go, R.A. Orlando, and M.G. Farquhar Expression of podocalyxin inhibits cell-cell adhesion and modifies junctional properties in Madin-Darby canine kidney cells Mol. Biol. Cell 11 9 2000 3219 3232
42. M. Schiffer, M. Bitzer, I.S. Roberts, J.B. Kopp, P. ten Dijke, P. Mundel, and E.P. Bottinger Apoptosis in podocytes induced by TGF-beta and Smad7 J. Clin. Investig. 108 6 2001 807 816
43. M. Schiffer, P. Mundel, A.S. Shaw, and E.P. Bottinger A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis J. Biol. Chem. 279 35 2004 37004 37012
44. Y.H. Kim, M. Goyal, D. Kurnit, B. Wharram, J. Wiggins, L. Holzman, D. Kershaw, and R. Wiggins Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat Kidney Int. 60 3 2001 957 968
45. S.U. Vogelmann, W.J. Nelson, B.D. Myers, and K.V. Lemley Urinary excretion of viable podocytes in health and renal disease Am. J. Physiol. Ren. Physiol. 285 1 2003 F40 48
46. A. Pozzi, G. Jarad, G.W. Moeckel, S. Coffa, X. Zhang, L. Gewin, V. Eremina, B.G. Hudson, D.B. Borza, R.C. Harris, and et al. Beta1 integrin expression by podocytes is required to maintain glomerular structural integrity Dev. Biol. 316 2 2008 288 301
47. R.V. Durvasula, and S.J. Shankland Podocyte injury and targeting therapy: an update Curr. Opin. Nephrol. Hypertens. 15 1 2006 1 7
48. B. Siu, J. Saha, W.E. Smoyer, K.A. Sullivan, and F.C. Brosius 3rd Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment BMC Nephrol. 7 2006 6
49. N. Tanji, G.S. Markowitz, C. Fu, T. Kislinger, A. Taguchi, M. Pischetsrieder, D. Stern, A.M. Schmidt, and V.D. D'Agati Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease J. Am. Soc. Nephrol. 11 9 2000 1656 1666
50. T. Miyata, C. van Ypersele de Strihou, and K. Kurokawa Baynes JW: alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications Kidney Int. 55 2 1999 389 399